Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10782304 | 0.86 | KMT2A (0.59) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL6276454 | 0.80 | KMT2A (0.53) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL4069065 | 0.79 | KMT2A (0.61) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL6543900 | 0.79 | KMT2A (0.67) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL2913624 | 0.79 | KMT2A (0.70) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL2039879 | 0.78 | KMT2A (1.00) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL11566827 | 0.78 | KMT2A (1.00) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL30446303 | 0.78 | KMT2A (1.00) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL23640082 | 0.77 | ALDH1A1 (0.52) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL19469362 | 0.77 | KMT2A (0.58) | KMT2AMEN1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114940658-A | Preparation process and preparation method of ceritinib | 山东华阳药业有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-118772116-A | 2, 4-Diaryl aminopyrimidine compound and preparation method and application thereof | 南通常佑药业科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-112574255-B | Organic arsine-based CDK inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-05-10 | — | — | CN | disclosed |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230338572-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | ANGIEX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-114940658-A | Preparation process and preparation method of ceritinib | 山东华阳药业有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-106336382-B | 4-saturated cyclic substituted aniline protein kinase inhibitor | 杭州雷索药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2021057867-A1 | CLASS OF CDK INHIBITOR BASED ON ORGANIC ARSINE, PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574255-A | Organic arsine-based CDK inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2021-03-30 | — | — | CN | disclosed |
| US-20120149900-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-06-14 | — | — | US | disclosed |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110054175-A1 | SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-03-03 | — | — | US | disclosed |
| WO-2009120795-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-5216138-A | With vinyl sulfonyl group | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | KMT2A 2551/4885MEN1 260/4885CA1 3940/4885 |
| US-20120149900-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | KMT2A 1417/4885MEN1 81/4885CA1 417/4885 |
| US-20230338572-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | TM9SF4, TM9SF2, TMPRSS4 | KMT2A 3053/4885MEN1 1738/4885CA1 1797/4885 |
| US-20110054175-A1 | SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS | PFAS, ODC1, AOC1 | KMT2A 1616/4885MEN1 405/4885CA1 1711/4885 |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | KMT2A 2551/4885MEN1 260/4885CA1 3940/4885 |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | KMT2A 1417/4885MEN1 81/4885CA1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.